// App-Quantinova.ai

: Deucravacitinib Improves Dermatology Life Quality Index (DLQI) in Patients With Moderate to Severe Psoriasis: Results From the Phase 3 POETYK PSO-1 and PSO-2 Trials

Researchers

Presenter

  • Matthias Augustin

Principal Investigators

  • Bruce Strober

  • April W Armstrong

  • Jennifer Beaumont

  • Tan P Pham

  • Stacie Hudgens

  • Joe Zhuo

  • Bron Becker

  • Subhashis Banerjee

  • Renata M Kisa

  • Kim Papp

Medical Centers

  • Institute for Health Services Research in Dermatology and Nursing (IVDP), University Medical Center Hamburg, Hamburg, Germany

  • Keck School of Medicine of University of Southern California, Los Angeles, CA

  • Clinical Outcomes Solutions, Tucson, AZ

  • Bristol-Myers Sqiubb, Princeton, NJ

  • Probity Clinical Research, Waterloo, ON, Canada

Locations

  • United States

  • Germany

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

  • Dermatology

Disease

  • Psoriasis

Biomarkers

  • N/A

Drug/Treatment

  • Apremilast

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved